CHIESI FARMACEUTICI S.P.A.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)
Phase 2
Terminated
- Conditions
- Neonatal Respiratory Distress Syndrome
- Interventions
- Drug: nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I)Other: nCPAP (nasal Continuous Positive Airway Pressure) alone (Part I)Drug: nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II)Other: nCPAP (nasal Continuous Positive Airway Pressure) alone (Part II)
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 166
- Registration Number
- NCT03235986
- Locations
- 🇮🇹
Prof.Carlo Dani, Coordinating Investigator - Careggi Hospital, Florence (Italy), Firenze, Italy
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)
Phase 3
Completed
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
- Interventions
- Drug: CHF 5993 100/6/12.5 µg
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 990
- Registration Number
- NCT03197818
- Locations
- 🇨🇳
Chiesi clinical Trial Site 156031, Beijing, Beijing, China
🇨🇳Chiesi Clinical Trial Site 156026, Beijing, Beijing, China
🇨🇳Chiesi clinical Trial Site 156017, Beijing, Beijing, China
A Study to Evaluate the Onset of Relief From Methacholine-induced Bronchoconstriction With CHF1535 NEXThaler in Asthmatic Patients.
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: CHF1535 NEXThalerDrug: CHF1535 pMDIDrug: Placebo
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2018-10-04
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 65
- Registration Number
- NCT03108534
- Locations
- 🇬🇧
University of Dundee, Dundee, United Kingdom
🇬🇧Hammersmith Medicines Research, London, United Kingdom
🇬🇧Medicines Evaluation Unit, Manchester, United Kingdom
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 67
- Registration Number
- NCT03086460
- Locations
- 🇺🇸
Chiesi Investigational Site, Richland, Washington, United States
A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary DiseaseCOPD
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 733
- Registration Number
- NCT03084796
- Locations
- 🇺🇸
Chiesi Investigational Site, Tacoma, Washington, United States
🇺🇸Clinical Trials Research, Lincoln, California, United States
🇺🇸Clinical Research Solutions, Dayton, Ohio, United States
An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: Placebo pMDIDrug: CHF 718 pMDIDrug: Beclomethasone Dipropionate (BDP)
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 610
- Registration Number
- NCT03084718
- Locations
- 🇺🇸
Chiesi Investigational Site, Greenfield, Wisconsin, United States
A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects
Phase 1
Completed
- Conditions
- Non-Cystic Fibrosis BronchiectasisCystic Fibrosis
- Interventions
- Drug: Placebo (Part 1 - SAD)Drug: CHF6333 (Part 1 - SAD)Drug: CHF6333 (Part 2 - MAD)Drug: Placebo (Part 2 - MAD)
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 72
- Registration Number
- NCT03056326
- Locations
- 🇧🇪
SGS Life Sciences, Antwerpen, Belgium
Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001
Phase 1
Completed
- Conditions
- Copd
- Interventions
- Drug: CHF5259 and CHF6001Drug: CHF5259 + placeboDrug: CHF6001 + placeboOther: Placebo
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2016-12-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 36
- Registration Number
- NCT03004495
- Locations
- 🇬🇧
Quintiles CPU, London, UK, United Kingdom
Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD
Phase 2
Completed
- Conditions
- COPD
- Interventions
- Drug: CHF 6001 Dose2Drug: CHF 6001 Dose1Other: Placebo
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 61
- Registration Number
- NCT03004417
- Locations
- 🇬🇧
Medicines Evaluation Unit Ltd, Manchester, United Kingdom
Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis
Phase 2
Completed
- Conditions
- Alpha-Mannosidosis
- Interventions
- Drug: Velmanase Alfa (e.g. Lamazym)
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 5
- Registration Number
- NCT02998879